The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients

NCT06723665 · tracked via the Priya Life Science China tracker

Sponsor

Affiliated Hospital of Jiangnan University

Phase

Not applicable

Started

2024-01-25

Last updated

2025-01-24

Condition(s) studied

Prostate Cancer

Investigational drug(s) / intervention(s)

18F-PSMA-100718F-FDG

18F-PSMA-1007: 18F-PSMA-1007 is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg

18F-FDG: 18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg

Study summary

micro-PET imaging showed that 18F-PSMA-1007 had similar or even better pharmacokinetics and imaging performance than 18F-DCFPyL. Due to the convenience of synthesis and good imaging performance, 18F-PSMA-1007 is expected to be popularized in clinical practice.The purpose of this study is to evaluate the performance of 18F-PSMA-1007 in diagnosis, differential diagnosis and efficacy monitoring of prostate cancer.

Eligibility

Sex

MALE

Min age

40 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: Prostate cancer is clinically suspected. The patient was diagnosed with prostate cancer by biopsy. Prostate cancer needs to be evaluated after treatment. Exclusion Criteria: Patients who did not meet the requirements as assessed by the investigator.

Primary outcome measure(s)

18F-PSMA-1007 PET/CT and 18F-FDG PCT/CT imaging were compared to determine the advantages of 18F-PSMA-PSMA PET/CT imaging for prostate cancer — 1 day
For patients receiving 18F-PSMA-1007 PET/CT, 18F-FDG PET/CT imaging was performed, and image visual analysis, semi-quantitative analysis and prognostic study were performed on PET/CT images. To evaluate the diagnosis, staging and prognosis of 18F-PSMA-1007

Trial sites (1)

Facility	City	Region	Status
Affiated Hospital of Jiangnan University	Wuxi	Jiangsu

More Affiliated Hospital of Jiangnan University trials in China

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies Enrolling by invitation

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors Enrolling by invitation

Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer Recruiting

Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients Enrolling by invitation

PET Image Exploration of Novel Tracer [68Ga]-FAPI-JNU Imaging Studies in Patients with Malignant Tumors Recruiting

Other trials for the same condition

A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC Recruiting

Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis Recruiting

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer Active, not recruiting

Adjuvant Chemotherapy for High Malignant Prostate Cancer Recruiting

Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06723665 on ClinicalTrials.gov ↗ ← All trials in China